Table 2.
Individual data for each of the participants (n = 10) included in the analyses.
| ParticipantNumber | Age at recruitment(years) | Sex | Type of AI | Total daily dose of HC (mg) | Frequency HC admin(per day) | Daily dose of MR-HC (mg) | Percentage change FM with MR-HCα | Percentage change LM with MR-HCα | Percentage change SMR with MR-HCα | Percentage change TMR with MR-HCα | Comorbidities |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | M | P | 30 | 2 | 30 | +1.7 | −2.6 | +5.5 | +7.7 | T2D; Hypertension Stroke; CKD Dyslipidaemia |
| 2 | 66 | F | P | 35 | 3 | 35 | −17.7 | +9.4 | +11.0 | +10.6 | Atrial Fibrillation |
| 3 | 66 | M | P | 15 | 2 | 20 | −12.7 | +27.3 | +11.8 | +3.3 | Hypothyroidism Obesity; Asthma |
| 4 | 37 | F | P | 22.5 | 3 | 25 | −22.2 | +12.4 | +2.4 | +0.7 | Hypothyroidism |
| 5 | 26 | M | P | 20 | 3 | 20 | −1.9 | +2.5 | +5.8 | +3.3 | - |
| 6 | 54 | M | P | 25 | 3 | 25 | −1.9 | −1.6 | +3.7 | −4.8 | Hypertension Depression |
| 7 | 21 | F | S | 17.5 | 3 | 20 | −22.2 | +12.4 | −4.0 | −2.2 | - |
| 8 | 87 | M | S | 20 | 3 | 20 | +2.2 | −2.8 | +18.5 | +6.1 | - |
| 9 | 70 | M | S | 25 | 3 | 25 | −9.8 | +0.9 | 0 | −4.5 | Hypertension |
| 10 | 68 | F | S | 20 | 3 | 20 | +2.2 | 0 | −4.5 | −5.3 | T1D Dyslipidaemia |
α= Data presented as a percentage of baseline values from HC metabolic study.
AI, adrenal insufficiency; BMI, body mass index; CKD, chronic kidney disease; F, female; FM, fat mass; HC, hydrocortisone; LM, lean mass; M, male; MR-HC, modified release hydrocortisone; P, primary; S, secondary; SMR, sleeping metabolic rate; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TMR, total metabolic rate.